ReviewTrends in endocrinology and metabolism: TEM2011
Androgen receptor-driven chromatin looping in prostate cancer.
Review in Trends in endocrinology and metabolism: TEM, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 51 citations in OpenAlex.
- Three-dimensional chromatin architecture is rapidly restored after DNA replication.Nature communications · 2026Article
- Molecular determinants of AR-enhancer interaction and cistrome reprogramming in prostate cancer progression.Endocrine-related cancer · 2026Review
- Testosterone and cancers: biological functions, molecular mechanisms and therapy.Molecular cancer · 2026Review
- Review
- Loss of feedback regulation between FAM3B and androgen receptor driving prostate cancer progression.Journal of the National Cancer Institute · 2024Article
- Long-range gene regulation in hormone-dependent cancer.Nature reviews. Cancer · 2023Review
- Complexities of Prostate Cancer.International journal of molecular sciences · 2022Review
- Review
- Re-Evaluate Fusion Genes in Prostate Cancer.Cancer informatics · 2021Article
- Chromosome Conformation Capture Reveals Two Elements That Interact with theInternational journal of molecular sciences · 2019Article
- Novel insights into chromosomal conformations in cancer.Molecular cancer · 2017Review
- Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.Hormones & cancer · 2017Article
- Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.Oncotarget · 2016Article
- Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability.EBioMedicine · 2016Article
- BRCA1 inhibits AR-mediated proliferation of breast cancer cells through the activation of SIRT1.Scientific reports · 2016Article
- The oncogene ERG: a key factor in prostate cancer.Oncogene · 2016Review
- Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.The EMBO journal · 2015Article
- The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells.The Journal of urology · 2015Article
- Article
- Hormone-induced and DNA demethylation-induced relief of a tissue-specific and developmentally regulated block in transcriptional elongation.The Journal of biological chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The androgen receptor (AR) is important for prostate cancer development and progression. Genome-wide mapping of AR binding sites in prostate cancer has found that the majority of AR binding sites are located within non-promoter regions. These distal AR binding regions regulate AR target genes (e.g. UBE2C) involved in prostate cancer growth through chromatin looping. In addition to long-distance gene regulation, looping has been shown to induce spatial proximity of two genes otherwise located far away along the genomic sequence and the formation of double-strand DNA breaks, resulting in aberrant gene fusions (e.g. TMPRSS2-ERG) that also contribute to prostate tumorigenesis. Elucidating the mechanisms of AR-driven chromatin looping will increase our understanding of prostate carcinogenesis and may lead to the identification of new therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.